New drug targets stubborn tumors in early trial
NCT ID NCT07460375
First seen Mar 11, 2026 · Last updated Apr 30, 2026 · Updated 9 times
Summary
This early-phase study tests a new drug called LCB02A in people with advanced solid tumors that have a specific protein (CLDN18.2) and have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 191 participants will take part in two phases: first to determine the best dose, then to test how well it works in certain tumor types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ASAN Medical Center
Seoul, 05505, South Korea
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Contact
-
Medical University of South Carolina
Charleston, South Carolina, 29406, United States
Contact
-
Princess Margaret Hospital
Toronto, Ontario, M5S 3H2, Canada
Contact
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
Contact
Conditions
Explore the condition pages connected to this study.